Overview

Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients.

Status:
Completed

Trial end date:
2017-09-15

Target enrollment:

Participant gender:

Summary

The overall objective of this trial is to identify a safe and effective treatment for visceral leishmaniasis (VL) in HIV co-infected Ethiopian patients. Patients will receive either Ambisome alone or Ambisome in combination with Miltefosine. Patients who do not undergo treatment failure will be given a VL prophylactic treatment with Pentamidine one month after the end of the study treatment.

Phase:

Phase 3

Details

Lead Sponsor:

Drugs for Neglected Diseases

Collaborators:

Addis Ababa University
Institute of Tropical Medicine, Belgium
London School of Hygiene and Tropical Medicine
Medecins Sans Frontieres, Netherlands
Slotervaart Hospital
University of Gondar

Treatments:

Amphotericin B
Liposomal amphotericin B
Miltefosine
Pentamidine